Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands

Dendritic cell (DC) vaccines have proven to be a valuable tool in cancer immune therapy. With several DC vaccines being currently tested in clinical trials, knowledge about their therapeutic value has been significantly increased in the past decade. Despite their established safety, it has become cl...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Maarten Versteven, Donovan Flumens, Diana Campillo-Davó, Hans De Reu, Laura Van Bruggen, Stefanie Peeters, Viggo Van Tendeloo, Zwi Berneman, Harry Dolstra, Sébastien Anguille, Willemijn Hobo, Evelien Smits, Eva Lion
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2022-02-01
Serie:	Frontiers in Immunology
Soggetti:	dendritic cells interleukin-15 programmed death (PD)-1 programmed death 1 ligand siRNA Wilms’ tumor 1 (WT1)
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.734256/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!